Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's recent climb.

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past six months.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are planned.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce competition in the weight-loss market.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an obesity drug.

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past six months.

Analysts predict the weight loss drug market to grow between $100 billion and $130 billion by 2030, as per a report.